COVID Led to Higher Clot Risk in Veterans With IBD
Get authentic, real-time news that helps you fight COVID-19 better.
Install PlexusMD App for doctors. It's free.
Older men with inflammatory bowel disease (IBD) had a higher chance of developing venous thromboembolism (VTE) after contracting COVID-19, researchers found in a case crossover study of veterans.

For IBD patients in the VA health system, SARS-CoV-2 infection was associated with an eight-fold increased likelihood of developing VTE, reported researchers.

However, when limited to patients on chronic anticoagulant medications, there was no significant association between COVID-19 and VTE in this group, the authors wrote in Gastroenterology.

One small study from pre-pandemic times suggested that IBD patients are at a two- to three-fold increased risk for developing VTE compared with the general population. And other research has demonstrated that the risk for VTE is even greater (by 16 fold) for non-hospitalized patients who present with active IBD. Meta-analysis data showed VTE has also been associated with a higher mortality risk for patients in the hospital.

For patients hospitalized with severe COVID-19, but who do not have confirmed or suspected VTE, the American Society of Hematology recommends use of anticoagulation as thromboprophylaxis.

However, no study has evaluated the risk of VTE for IBD patients who contract COVID-19. The pathogenesis of VTE is complex and multifactorial in IBD, which can be further complicated by a COVID-19 infection, Khan and co-authors said.

"In patients with infections such as COVID-19, endothelial dysfunction caused by the infectious process increases thrombin production and terminates fibrinolysis, which in turn promotes a hypercoagulable state," they wrote. "Although these mechanisms cannot be completely explained by traditional VTE risk factors, it stands to reason that contracting SARS-CoV-2 infection would confer an additional risk on top of the already elevated risk in patients with IBD."

For their study, the researchers examined data on IBD patients from the VA healthcare system who reported a VTE event from April 1, 2020 to March 30, 2021.

Overall, there were 428 participants included in this study, with an average age of 69. Nearly all were men and about 80% were white, with 54% having a diagnosis of ulcerative colitis and 46% having Crohn's disease. Half of the patients were taking 5-aminosalicylic acid.

The most common pre-existing conditions among participants were hypertension (58%), diabetes mellitus (31%), and arrhythmia (20%). Chronic anticoagulant use was reported in 31% of patients.

There were 13.6% of participants who contracted COVID-19. Among these, 21 contracted the virus within 30 days before experiencing VTE. Furthermore, there were 5.1% of IBD patients hospitalized due to COVID-19 infection.

The authors found a substantially higher VTE risk in patients who were not taking anticoagulant medications prior to COVID-19 infection.

"The data suggest that IBD patients who contract SARS-CoV-2 have a substantially increased risk of VTE and may therefore benefit from prophylaxis," authors stated.